Other
Interleukin inhibitors for arthritis, psoriasis and bowel disease
Interleukin inhibitor, biologic
Other names: ustekinumab, Stelara, secukinumab, Cosentyx, ixekizumab, Taltz
Wait
2 weeks
ground trial when starting
Different waits apply in other cases.
Examiner
The examiner can issue when the document's criteria are met
FAA label
ACCEPTABLE
The FAA lists these interleukin inhibitors as acceptable biologics when the underlying condition qualifies, with a two-week ground trial when starting and four hours of no-fly after each dose, and a warning for posterior reversible encephalopathy syndrome (PRES).
Track your medicationsMore detail: Interleukin inhibitors for arthritis, psoriasis and bowel diseaseThe rest of Crosscheck's reading, in plain wordsOpen
Wait
- 4 hours no-fly after each dose
- a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication
Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.
- 14 days after starting: ground observation
- 4 hours after each dose: no flying
Show the FAA's words: Interleukin inhibitors for arthritis, psoriasis and bowel diseaseThe official FAA wording: two passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
ACCEPTABLE BIOLOGICS - MONOTHERAPY MEDICATION Permitted if the underlying condition qualifies; consult the condition pages for details.
Interleukin Inhibitor: anakinra (Kineret), bimekizumab (Bimzelx), guselkumab (Tremfya), ixekizumab (Taltz), mirikizumab (Omvoh), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tildrakizumab (Ilumya), tocilizumab (Actemra), ustekinumab (Stelara). Warn for posterior reversible encephalopathy syndrome (PRES), 4 hours
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.